Berkeley, CA-based Dynavax, a vaccine maker, is buying Germany's Rhein Biotech from Crucell for $12 million. Dynavax gains a European-certified vaccine manufacturing plant and new antigens for its clinical program. Dynavax says the deal will help it develop a diversified vaccine franchise.
- read the East Bay Business Journal report